NCT03175432

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Active, enrolled Phase 2 Last updated 15 April 2026

What this trial tests

Phase 2 trial testing Atezolizumab in BRAF V600 Wild Type in 29 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 June 2017

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	15 June 2017
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across United States

Drugs / interventions tested

• Atezolizumab (atezolizumab) — full drug profile →
• Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
• Cobimetinib (cobimetinib) — full drug profile →
• Quality-of-Life Assessment

Conditions studied

• BRAF V600 Wild Type — all drugs for BRAF V600 Wild Type →
• Clinical Stage IV Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage IV Cutaneous Melanoma AJCC v8 →
• Intracranial Melanoma — all drugs for Intracranial Melanoma →
• Metastatic Malignant Neoplasm in the Brain — all drugs for Metastatic Malignant Neoplasm in the Brain →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with BRAF V600 Wild Type or Clinical Stage IV Cutaneous Melanoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well bevacizumab and atezolizumab with or without cobimetinib work in treating patients with untreated melanoma that has spread to the brain (brain metastases). Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if giving bevacizumab and atezolizumab with or without cobimetinib will work better in treating patients with melanoma brain metastases.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Melanoma treatment in review.
   Domingues B, Lopes JM, Soares P, Pópulo H. · · 2018 · cited 432× · PMID 29922629 · DOI 10.2147/itt.s134842
2. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
   Giannone G, Ghisoni E, Genta S, Scotto G, et al · · 2020 · cited 119× · PMID 32575899 · DOI 10.3390/ijms21124414
3. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
   Liu Z, Wang Y, Huang Y, Kim BYS, et al · · 2019 · cited 88× · PMID 31331639 · DOI 10.1016/j.tips.2019.07.001
4. Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers.
   Sevenich L. · · 2019 · cited 84× · PMID 30941312 · DOI 10.3389/fonc.2019.00163
5. Immunotherapy of brain metastases: breaking a "dogma".
   Di Giacomo AM, Valente M, Cerase A, Lofiego MF, et al · · 2019 · cited 69× · PMID 31623643 · DOI 10.1186/s13046-019-1426-2
6. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
   Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
7. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.
   Comunanza V, Bussolino F. · · 2017 · cited 62× · PMID 29270405 · DOI 10.3389/fcell.2017.00101
8. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.
   Kamath SD, Kumthekar PU. · · 2018 · cited 60× · PMID 30319977 · DOI 10.3389/fonc.2018.00414